Leprán I, Papp J G
Department of Pharmacology, Albert Szent-Györgyi Medical University, Szeged, Hungary.
J Cardiovasc Pharmacol. 1994;24 Suppl 1:S9-15. doi: 10.1097/00005344-199424001-00003.
The aim of the present study was to investigate the influence of moxonidine, a representative of I1-imidazoline-receptor agonist, on arrhythmias induced by myocardial ischemia or reperfusion. Acute myocardial infarction was produced by tightening a previously placed loose silk loop around the coronary artery in conscious rats. Moxonidine (0.01, 0.03, or 0.10 mg/kg i.v., 10 min before coronary ligation) significantly decreased the incidence of ventricular tachycardia during the first 15 min of infarction (70 versus 100% in controls), and the number of animals that survived without developing any arrhythmia was increased (15, 20, and 25%, respectively, versus 0%). Reperfusion-induced arrhythmias were produced by releasing a snare after 6 min of myocardial ischemia in anesthetized, artificially ventilated rats. Reperfusion rapidly induced severe dysrhythmias in all of the control animals. Moxonidine pretreatment (0.03 and 0.10 mg/kg) decreased the incidence of ventricular fibrillation (25 and 30% versus 64%) and increased the number of animals that survived without developing any arrhythmia (20 and 25% versus 0%). We conclude that moxonidine offers significant protection against the development of arrhythmias induced by acute regional myocardial ischemia in conscious rats. Moxonidine pretreatment also provides a beneficial effect during reperfusion-induced arrhythmias that appear after a brief period of myocardial ischemia.
本研究的目的是探讨I1-咪唑啉受体激动剂代表药物莫索尼定对心肌缺血或再灌注所致心律失常的影响。通过收紧清醒大鼠冠状动脉上预先放置的宽松丝线环来制造急性心肌梗死。莫索尼定（静脉注射0.01、0.03或0.10 mg/kg，在冠状动脉结扎前10分钟给药）显著降低梗死最初15分钟内心室性心动过速的发生率（对照组为70%，而莫索尼定组为100%），且未发生任何心律失常而存活的动物数量增加（分别为15%、20%和25%，而对照组为0%）。在麻醉、人工通气的大鼠中，通过在心肌缺血6分钟后松开圈套器来诱发再灌注性心律失常。再灌注迅速在所有对照动物中诱发严重的心律失常。莫索尼定预处理（0.03和0.10 mg/kg）降低了心室颤动的发生率（分别为25%和30%，而对照组为64%），并增加了未发生任何心律失常而存活的动物数量（分别为20%和25%，而对照组为0%）。我们得出结论，莫索尼定对清醒大鼠急性局部心肌缺血所致心律失常的发生具有显著的保护作用。莫索尼定预处理对短暂心肌缺血后出现的再灌注性心律失常也有有益作用。
